Digoxin in Atrial Fibrillation: An Old Topic Revisited

Area of Science:

• Cardiology
• Pharmacology

Background:

• Digoxin has been a mainstay for over 50 years in managing Atrial Fibrillation (AF), primarily for heart rate (HR) control and rhythm restoration.
• Concerns regarding digoxin's association with increased mortality have emerged over the past two decades, primarily from observational studies and post-hoc analyses.

Purpose of the Study:

• To critically review the therapeutic application of digoxin in AF management.
• To analyze existing mortality data, considering study limitations and biases.
• To emphasize the importance of rigorous serum level monitoring for digoxin in clinical practice.

Main Methods:

• Literature review and critical analysis of existing studies on digoxin use in AF.
• Evaluation of data from cross-sectional studies and post-hoc analyses of Randomized Controlled Trials (RCTs).
• Assessment of evidence regarding digoxin's impact on mortality in AF patients.

Main Results:

• Despite potential biases in current evidence, digoxin remains a frequently prescribed medication for AF globally.
• Existing studies suggest a correlation between digoxin therapy and increased mortality, though definitive causal links are debated.
• The lack of dedicated RCTs on mortality makes conclusive statements challenging.

Conclusions:

• Digoxin's role in AF requires careful consideration due to conflicting safety data.
• Enhanced vigilance and strict monitoring of serum digoxin levels are crucial for optimizing patient outcomes.
• Further rigorous research, potentially including dedicated RCTs, is needed to definitively ascertain digoxin's safety profile in AF.